What important information is included in the labeling for ibrutinib/ibrutinib?

Ibrutinib/Ibrutinib (Ibrutinib) is an oral small molecule targeted drug that is widely used to treat a variety of B cell malignant diseases. It interferes with the B cell receptor (BCR) signaling pathway by irreversibly inhibiting Bruton tyrosine kinase (BTK), blocking the growth and survival of malignant B cells. The drug was jointly developed by Pharmacyclics and Janssen and has been approved by the US FDA and multiple national drug regulatory agencies for the treatment of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenstrom's macroglobulinemia (WM) and chronic graft-versus-host disease (cGVHD).

According to the overseas drug instructions, the core information of ibrutinib covers the scope of indications, dosage recommendations, dosage methods, adverse reactions and potential drug interactions.

1. First of all, in terms of indications, ibrutinib covers several common chronic B cell diseases. In CLL and SLL, it is applicable to previously treated patients, as well as to untreated patients with high-risk biomarkers such as 17p deletions or TP53 mutations. In WM, ibrutinib has shown promising results as a single agent or in combination with rituximab. In the management of cGVHD, ibrutinib is the first oral targeted drug approved for use in children and adults aged 12 years and older. It is mainly used for patients with cGVHD who have failed previous treatments.

2. In terms of dosage, the standard recommendation is 420 mg once a day for CLL, SLL, WM and cGVHD patients over 12 years old. For children with cGVHD between 1 and 12 years old, the dose is calculated based on body surface area and is 240 mg/m²/day, but the maximum dose should not exceed 420 mg. All dosage forms are capsules or tablets, which should be swallowed whole and should not be broken or chewed. It is recommended to take them regardless of food, but they need to be taken regularly every day to ensure stable blood concentration.

3. One of the important concerns during the treatment of ibrutinib is its adverse reaction characteristics. Common side effects include diarrhea, fatigue, rash, thrombocytopenia, neutropenia, bleeding tendencies, joint pain, and irregular heartbeats (especially atrial fibrillation). For the elderly or patients with cardiovascular disease, electrocardiogram and coagulation function should be closely monitored. In addition, ibrutinib has the potential risk of causing infection, pneumonia and bleeding events, so concomitant use with anticoagulants or antiplatelet drugs should be avoided during treatment unless clearly clinically necessary.

4. In terms of drug interactions, ibrutinib is mainly metabolized by CYP3A4. Therefore, combined use with strong CYP3A inhibitors (such as ketoconazole, clarithromycin) or inducers (such as rifampicin) may significantly affect the blood concentration of the drug, and even lead to toxic reactions or decreased efficacy. Careful evaluation is required during combined use, and the dose of ibrutinib should be adjusted if necessary, or other alternative treatments should be considered.

5. It is important to note that ibrutinib is not recommended for pregnant or lactating women, and it is also recommended that male patients use effective contraceptive measures to avoid potential genetic risks. In addition, if serious adverse reactions are encountered during treatment (such as liver function damage, severe infection, severe skin reaction, etc.), the medication must be interrupted in time, and the dosage must be evaluated and adjusted according to the condition.

From the perspective of global clinical experience, ibrutinib has opened a new era for targeted treatment of B cell-related diseases, but it also puts forward higher requirements for individualized treatment and risk management. During the period of treatment with ibrutinib, patients should maintain close communication with professional physicians and regularly review blood and ECG indicators in order to promptly detect and intervene in possible adverse events and ensure the continuity and safety of treatment.

Reference materials:https://www.imbruvica.com/